Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | Director | June 12, 2026 | June 15, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | May 21, 2025 | May 23, 2025 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2036-06-12 | Direct | 87,900 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 87,900 · Balance 87,900 F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
ILLUMINA, INC.
Report date May 21, 2025 · Filed May 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,139 |
Reported balance
After 2025-05-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 3,780 · Balance 22,139 F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. F2: In connection with Illumina's spin out of Grail, Inc., which was completed on June 24, 2024, all unvested equity award units were adjusted pursuant to Illumina's Amended and Restated 2015 Stock and Incentive Plan. Dr. Epstein's unvested RSUs were increased by 53 units as a result of such adjustment. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date.
F2: In connection with Illumina's spin out of Grail, Inc., which was completed on June 24, 2024, all unvested equity award units were adjusted pursuant to Illumina's Amended and Restated 2015 Stock and Incentive Plan. Dr. Epstein's unvested RSUs were increased by 53 units as a result of such adjustment.
VERACYTE, INC.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,718 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,272 · Balance 57,718 F1: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 20:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 87,900 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001193125-26-271083 · ownership.xml · derivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,900 Underlying: Common Stock · 87,900 shares Expires 2036-06-12 F1 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:55 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 5,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001252004-26-000004 · wk-form4_1781556952.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,718 F1 · kind: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:39 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 10,000 | $44.01 | $440,129.00 |
DisclosureSEC source: 0001252004-26-000002 · wk-form4_1779482346.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,446 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 5, 2025. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $44.00 to $44.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| May 05, 2026 Filed May 6, 2026 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001193125-26-208899 · ownership.xml · derivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2026-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option vested and became exercisable on the date of the 2017 Annual Meeting of Stockholders. Read SEC document |
| May 05, 2026 Filed May 6, 2026 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 25,000 | $1.69 | $42,250.00 |
DisclosureSEC source: 0001193125-26-208899 · ownership.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001252004-25-000005 · wk-form4_1759522571.xml · derivative · entry 3 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 5, 2025. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 21,473 | $35.08 | $753,204.13 |
DisclosureSEC source: 0001252004-25-000005 · wk-form4_1759522571.xml · nonDerivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,446 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 5, 2025. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $35.00 to $35.30. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $7.94 | $79,400.00 |
DisclosureSEC source: 0001252004-25-000005 · wk-form4_1759522571.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 5, 2025. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 9,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000096 · wk-form4_1750709399.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,919 F1 · kind: Restricted stock units awarded on June 18, 2025 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| May 29, 2025 Filed May 30, 2025 20:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000950170-25-079712 · ownership.xml · derivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-05-29 F1 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:08 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 3,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015513 · form4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,139 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. F2 · balance_after: In connection with Illumina's spin out of Grail, Inc., which was completed on June 24, 2024, all unvested equity award units were adjusted pursuant to Illumina's Amended and Restated 2015 Stock and Incentive Plan. Dr. Epstein's unvested RSUs were increased by 53 units as a result of such adjustment. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 21:47 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001384101-25-000004 · wk-form4_1736372816.xml · derivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 21:47 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 20,000 | $8.04 | $160,800.00 |
DisclosureSEC source: 0001384101-25-000004 · wk-form4_1736372816.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:35 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001384101-24-000165 · wk-form4_1731620137.xml · derivative · entry 3 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 15,000 shares Expires 2025-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 9, 2024. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:35 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 15,000 | $38.32 | $574,830.00 |
DisclosureSEC source: 0001384101-24-000165 · wk-form4_1731620137.xml · nonDerivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,598 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 9, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $38.00 to $38.73. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:35 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 15,000 | $8.04 | $120,600.00 |
DisclosureSEC source: 0001384101-24-000165 · wk-form4_1731620137.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 9, 2024. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 11,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-24-000101 · wk-form4_1718657299.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,598 F1 · kind: Restricted stock units awarded on June 13, 2024 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:28 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0000950170-24-071945 · ownership.xml · derivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-07 F1 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| May 16, 2024 Filed May 17, 2024 22:17 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 2,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015931 · form4.xml · nonDerivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,306 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 22:17 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 612 | $115.01 | $70,386.12 |
DisclosureSEC source: 0001127602-24-015931 · form4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,684 Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:21 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 9,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-23-000121 · wf-form4_168669124778366.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,125 F1 · kind: Restricted stock units awarded on June 9, 2023 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 20:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001209191-23-035049 · doc4.xml · derivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-06 F1 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 6, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| May 26, 2023 Filed May 31, 2023 20:56 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-017237 · form4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,296 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 25, 2023 Filed May 25, 2023 20:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,600 | $0.00 Strike: $71.09 | $0.00 |
DisclosureSEC source: 0001127602-23-016874 · form4.xml · derivative · entry 3 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,600 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2023 Filed May 25, 2023 20:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 7,600 | $71.09 | $540,284.00 |
DisclosureSEC source: 0001127602-23-016874 · form4.xml · nonDerivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 492 | $212.65 | $104,623.80 |
DisclosureSEC source: 0001127602-23-016874 · form4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,164 Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 00:12 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 14,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000098 · wf-form4_165542475995558.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,451 F1 · kind: Restricted stock units awarded on June 16, 2022 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:40 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 11,893 | $0.00 Strike: $23.48 | $0.00 |
DisclosureSEC source: 0001209191-22-036345 · doc4.xml · derivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,893 Underlying: Common Stock · 11,893 shares Expires 2032-06-09 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:40 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 8,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036345 · doc4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,331 F1 · security: Award of restricted stock units that vest in full on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| May 26, 2022 Filed May 27, 2022 23:30 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015920 · form4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,656 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 20:21 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 8,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000114 · wf-form4_162335648610256.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 F1 · kind: Restricted stock units awarded on June 8, 2021 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:29 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 4,334 | $0.00 Strike: $68.94 | $0.00 |
DisclosureSEC source: 0000899243-21-022085 · doc4.xml · derivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,334 Underlying: Common Stock · 4,334 shares Expires 2031-06-01 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:29 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 2,681 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022085 · doc4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,681 F1 · security: Award of restricted stock units that vest in full on the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| May 26, 2021 Filed May 27, 2021 21:27 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 881 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018202 · form4.xml · nonDerivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,424 F1 · security: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 21:27 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 385 | $397.09 | $152,879.65 |
DisclosureSEC source: 0001127602-21-018202 · form4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,543 Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:26 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001437749-20-015124 · rdgdoc.xml · derivative · entry 5 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 10, 2020. F5 · derivative.exercise_date: The option is fully vested. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:26 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,854 | $30.51 | $56,566.10 |
DisclosureSEC source: 0001437749-20-015124 · rdgdoc.xml · nonDerivative · entry 4 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 10, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.44 to $30.61. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:26 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,583 | $29.92 | $167,023.82 |
DisclosureSEC source: 0001437749-20-015124 · rdgdoc.xml · nonDerivative · entry 3 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,854 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 10, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $29.42 to $30.41. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:26 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,563 | $28.74 | $73,661.90 |
DisclosureSEC source: 0001437749-20-015124 · rdgdoc.xml · nonDerivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,437 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 10, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.38 to $29.35. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 00:26 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 10,000 | $5.28 | $52,800.00 |
DisclosureSEC source: 0001437749-20-015124 · rdgdoc.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 10, 2020. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:33 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.30 | $0.00 |
DisclosureSEC source: 0001384101-20-000089 · wf-form4_159173477205679.xml · derivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-07 F1 · derivative.exercise_date: The option becomes exercisable in full on June 8, 2021 or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document |
| May 27, 2020 Filed May 28, 2020 22:02 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 963 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018078 · form4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,928 F1 · security: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 16,000 | Not disclosed Strike: $26.59 | Not disclosed |
DisclosureSEC source: 0001209191-20-027078 · doc4.xml · derivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-05-01 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 1, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:50 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $27.01 | $0.00 |
DisclosureSEC source: 0001384101-19-000082 · wf-form4_156045902027263.xml · derivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The option becomes exercisable in full on June 12, 2020 or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document |
| May 29, 2019 Filed May 30, 2019 21:23 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-020249 · form4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,965 F1 · security: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| May 23, 2019 Filed May 29, 2019 00:35 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 589 | $308.97 | $181,983.33 |
DisclosureSEC source: 0001127602-19-020063 · form4.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,667 Read SEC document |
| May 03, 2019 Filed May 7, 2019 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 16,000 | Not disclosed Strike: $17.15 | Not disclosed |
DisclosureSEC source: 0001209191-19-027946 · doc4.xml · derivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-05-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 3, 2020 or (ii) the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:18 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $51.17 | $0.00 |
DisclosureSEC source: 0001127602-19-017302 · form4.xml · derivative · entry 6 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:18 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 200 | $312.17 | $62,433.00 |
DisclosureSEC source: 0001127602-19-017302 · form4.xml · nonDerivative · entry 5 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,256 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F5 · price: Weighted average sale price representing 200 shares sold ranging from $312.11 to $312.22 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:18 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,372 | $311.23 | $427,001.93 |
DisclosureSEC source: 0001127602-19-017302 · form4.xml · nonDerivative · entry 4 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,456 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F4 · price: Weighted average sale price representing 1,372 shares sold ranging from $310.95 to $311.81 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.